glp-1 constipation lawsuit in louisiana filed against makers of Ozempic and Mounjaro Patients claim blindness, bowel injuries

PlexusDx supports precision-wellness by revealing genetic predispositions in GLP-1 pathways, enabling more personalized conversations about treatment duration, adjustment, and safe cessation protocols with your provider

Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results

This leads to systematic underestimation of slow transit and outlet dysfunction prevalence

Hold or extend: Maintain 5 mg/day, or extend toward 10 mg/day for the optional days 1120 window if tolerated